23:13 , Aug 28, 2017 |  BC Extra  |  Politics & Policy

FDA steps up enforcement, regulation of stem cell therapies

FDA said it is taking steps to rein in unscrupulous stem cell therapies while at the same time advancing regulatory measures to encourage development of safe and scientifically proven stem cell treatments. In a statement...
22:06 , May 11, 2017 |  BC Innovations  |  Tools & Techniques

Stemming the tide

OncoMed’s bad April has all the hallmarks of a death knell for the once-promising technology of cancer stem cells, adding to the pile of preclinical breakthroughs that didn’t translate to the clinic. But many insiders...
08:00 , Jan 28, 2016 |  BC Innovations  |  Strategy

CIRM's endgame

In the latest effort to make good on promises made to the voters who created the California Institute for Regenerative Medicine (CIRM) in 2004, the agency has approved a strategic plan spelling out concrete goals...
03:17 , Dec 16, 2014 |  BC Extra  |  Financial News

CIRM 2.0: New urgency for therapeutic development

Ten years after California voters passed Proposition 71 on the promise that stem cell technology would produce new therapies, the board of the the California Institute for Regenerative Medicine (CIRM) last week unanimously approved $50...
07:00 , Oct 27, 2014 |  BC Week In Review  |  Company News

Rockefeller University, NeoStem deal

The university granted NeoStem exclusive rights to patents covering the use of dendritic cell immunotherapies. The partners could not be reached for financial terms. NeoStem said the patents relate to its dendritic cell/tumor cell technology,...
07:00 , May 19, 2014 |  BC Week In Review  |  Company News

California Stem Cell, Cellular Biomedicine, NeoStem deal

NeoStem completed its acquisition of stem cell company California Stem Cell for 5.3 million shares, or about $24.5 million based on NeoStem's close of $4.59 on May 8, before the deal closed. California Stem Cell...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Company News

California Stem Cell, NeoStem deal

NeoStem will acquire stem cell company California Stem Cell for 5.3 million shares, or about $34.1 million based on NeoStem's close of $6.40 on April 11, before the deal was announced. California Stem Cell is...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Clinical News

Melapuldencel-T: Phase I data

An open-label, Chinese Phase I trial in 8 patients with HCC showed that once-weekly subcutaneous TC-DC plus GM-CSF for 3 weeks following standard tumor resection and transarterial chemoembolization (TACE) did not lead to any adverse...
07:00 , Mar 20, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

At least $440 million in new support for public-private partnerships was allocated last month globally. Almost $230 million of that amount is earmarked for the NIH 's Accelerating Medicines Partnership 1 ( see "Selected public-private...
08:00 , Feb 27, 2014 |  BC Innovations  |  Tools & Techniques

(Pluri)potent acid

Academics and companies alike are scrambling-and thus far failing-to reproduce a surprisingly simple method for generating pluripotent mouse stem cells that uses an external stress stimulus to trigger reprogramming. Whether the method simply does not...